CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The OPENCORONA project aims to develop a DNA vaccine to protect against the 2019-nCoV infection through a phase I clinical trial. Utilizing a rapid vaccine platform, the project focuses on generating effective candidates and testing them in animal models before advancing to human trials.
The OPENCORONA consortia will test a therapy that protects against 2019-nCoV infection and/or disease in a phase I clinical trial in 24 months.
The spread of the 2019-nCoV (or SARS-CoV-2) between the Jan 21 and Feb 11 has expanded alarmingly.
There are >43000 confirmed cases of which >1000 has died.
Around 7000 have a severe disease.
The infection still mainly affect mainland China, although an increasing number of cases are seen outside China.
The major question is what will happen when China h…
KAROLINSKA INSTITUTET
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Giessen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Italy, Carpi Mo
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Sweden, Matfors
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
